<DOC>
	<DOC>NCT03069352</DOC>
	<brief_summary>This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of venetoclax co-administered with low dose cytarabine (LDAC) versus LDAC co-administered with placebo in treatment naïve participants with acute myeloid leukemia (AML) who are ineligible for intensive induction chemotherapy.</brief_summary>
	<brief_title>A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Participants must have histological confirmation of Acute Myeloid Leukemia (AML) by World Health Organization (WHO) criteria, is ineligible for intensive induction chemotherapy. Participants must have adequate renal and liver function. Participant received any prior treatment for AML with the exception of hydroxyurea, allowed through the first cycle of study treatment. Participant had an antecedent myeloproliferative neoplasm (MPN) including myelofibrosis, essential thrombocytosis, polycythemia vera, or chronic myelogenous leukemia (CML) with or without BCRABL mutation. Participant that has acute promyelocytic leukemia (APL). Participant has known central nervous system (CNS) involvement with AML. Participant has known Human Immunodeficiency Virus (HIV) infection, known to be positive for hepatitis B virus (HBV), or hepatitis C virus (HCV) infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Treatment naïve</keyword>
	<keyword>Venetoclax</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Cytarabine</keyword>
</DOC>